{
    "clinical_study": {
        "@rank": "68892", 
        "arm_group": {
            "arm_group_label": "Losmapimod (GW856553X)", 
            "arm_group_type": "Experimental", 
            "description": "The subjects will be administered with 7.5 mg (1 tablet) of losmapimod following the completion of the Baseline (time zero) assessments. Subjects will continue to take one tablet in the morning and one tablet in the evening for approximately 2 weeks. After all the pre-dose assessments are completed at the Week 2 visit, subjects will be administered the first 15 mg (2 tablets) dose. Subjects will continue to take two tablets in the morning and two tablets in the evening every day for approximately 22 weeks. Doses of study treatment will be separated by at least 6 hours"
        }, 
        "brief_summary": {
            "textblock": "This is a single-arm, multicenter, open-label Phase II, proof-of-mechanism study to evaluate\n      the efficacy, safety, tolerability, and pharmacokinetics of losmapimod in approximately 21\n      subjects with primary (idiopathic) FSGS. FSGS patients with nephrotic range proteinuria\n      (urinary protein/creatinine [Up/c] ratio >3) and a history of steroid or calcineurin\n      inhibitor resistance, including relapse of proteinuria after steroid or calcineurin\n      inhibitor treatment will be included. Losmapimod will be orally administered twice daily\n      over a 24-week treatment phase followed by a 12-week follow-up for safety and relapse\n      assessments."
        }, 
        "brief_title": "A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Glomerulosclerosis, Focal Segmental", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulosclerosis, Focal Segmental", 
                "Proteinuria"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is between 18 and 65 years of age inclusive and has a body mass index (BMI)\n             less than 35 kilograms(kg)/meter(m)^2.\n\n          -  Subject has a clinical diagnosis of primary (idiopathic) FSGS made in the last 36\n             months or less as verified by renal biopsy (light microscopy, immuno-fluorescence,\n             and/or by electron microscope). This must be confirmed by independent review of the\n             histopathology report and/or biopsy specimen(s) by the study central pathologist.\n\n          -  Subject has FSGS resistant to corticosteroids or calcineurin inhibitors as defined by\n             the Investigator and/or by guidelines and has not utilized a second FSGS-directed\n             agent.  Resistance includes the inability to obtain sustained remission (i.e.\n             occurrence of relapse). Up to approximately 5 subjects will be enrolled in whom the\n             investigator considers corticosteroids to be contraindicated (Subjects who are obese,\n             pre-diabetic, elderly, have prior intolerance to corticosteroids and/or are\n             anticipated to have a poor response to corticosteroids).\n\n          -  Subjects will have nephrotic range proteinuria, as indicated by a spot Up/c or 24\n             hour urine total protein measure > 3.0.  The Up/c will be assessed by the average of\n             triplicate measures from first morning voids separated by a minimum of 24 hours and\n             differing by =<50%. Furthermore subjects must have had active disease with nephrotic\n             proteinuria (i.e.:24 hour or spot Up/c >3.0) for at least 2 months prior to\n             screening, despite background therapy.\n\n          -  A female subject is eligible to participate if she is of non-childbearing potential;\n             criteria to be considered of 'non-childbearing potential' as described in the\n             protocol.\n\n          -  A female subject is eligible to participate if she is of child-bearing potential.\n             Females of child-bearing potential must agree to use two of the approved\n             contraception methods listed in the protocol from 14 days before the first dose of\n             study drug until 30 days after the last dose of study drug.  Only females of\n             child-bearing potential with negative pregnancy test, as determined by serum human\n             chorionic gonadotropin (hCG) test at screening and urine hCG test prior to dosing at\n             baseline visit and during the study at the indicated times, will be administered\n             losmapimod.\n\n          -  Subject is capable of giving written informed consent, which includes compliance with\n             the requirements and restrictions listed in the consent form and is willing and able\n             to return for all study visits.\n\n        Exclusion Criteria:\n\n          -  Subject has been administered FSGS-directed agents other than corticosteroids or\n             calcineurin inhibitors prescribed to lower proteinuria. These include but are not\n             limited to: Rituximab and any other biologic investigational agent; cyclophosphamide,\n             chlorambucil, mycophenolate mofetil, azathioprine, and rapamycin (sirolimus).\n\n          -  Subject has received a live vaccine within 28 days of first study treatment.\n\n          -  Subject has collapsing FSGS lesion.\n\n          -  Subject has secondary FSGS or renal impairment from a condition that is not FSGS.\n             Causes of secondary FSGS include but are not limited to: Drugs and toxins:\n             analgesics, heroin, cocaine and pamidronate; Infectious or parasitic diseases:\n             Hepatitis B, Hepatitis C, HIV (known as HIV-Associated Nephropathy), parvovirus;\n             Adaptive structural-functional response likely mediated by glomerular\n             hypertrophy/hyperfiltration: Hemodynamic factors - With reduced renal mass: solitary\n             kidney allograft, renal dysplasia, renal agenesis, oligomeganephronia, segmental\n             hypoplasia, vesicoureteric reflux; Hemodynamic causes - Without reduced renal mass:\n             sickle cell nephropathy, congenital cyanotic heart disease, hypertension;\n             Malignancies: Lymphomas and other malignancies; for skin or cervical cancer consult\n             medical monitor; Diabetic Nephropathy; Other forms of glomerular nephropathy: focal\n             proliferative glomerulonephritis (IgA nephropathy, lupus, nephritis, pauci-immune\n             focal necrotizing and crescentic glomerulonephritis), hereditary nephritis,\n             hypertensive arterionephrosclerosis, membranous glomerulopathy, thrombotic\n             microangiopathies; Miscellaneous: Alport syndrome, sarcoidosis, radiation nephritis;\n             Genetic forms of FSGS (e.g. patient is known to carry genetic mutation).\n\n          -  History of congestive heart failure.\n\n          -  History of diabetes mellitus type 1 or 2.\n\n          -  History of a major organ transplant (e.g., heart, lung, kidney, liver) or\n             hematopoietic stem cell/marrow transplant.\n\n          -  Clinically significant systemic illness or infection within the last 28 days (e.g.\n             chronic persistent or acute infection) that is likely to result in deterioration of\n             the subject's condition or affect the subject's safety during the study.\n\n          -  Any condition or situation, including clinically significant abnormalities in\n             screening laboratory assessments (not related to the disease), which in the opinion\n             of the Investigator could confound the results of the study or put the subject at\n             undue risk.\n\n          -  History of sensitivity or intolerance to the study treatment (i.e. losmapimod), or a\n             history of drug or other allergy that in the opinion of the Investigator or GSK\n             Medical Monitor contraindicates participation.\n\n          -  Estimated GFR <45 milliliter(mL)/minutes(min)/1.73m^2 (using 4-variable Modification\n             of Diet in Renal Disease [MDRD] formula) at screening.\n\n          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2xUpper Limit\n             of Normal (ULN); alkaline phosphatase and bilirubin >1.5xULN (isolated bilirubin\n             >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).\n\n          -  Single time measurement of a portion of heart beat (QTc) value obtained over a brief\n             recording period: QTc >=450 milliseconds (msec) (machine or manual overread); or QTc\n             >=480 msec in subjects with Bundle Branch Block. If a single QTc is abnormal, then\n             the averaged QTc values of triplicate electrocardiograms (ECGs) obtained (each\n             separated by at least 5 min) will be utilize to determine eligibility.\n\n          -  Hypertensive as defined as blood pressure (BP) >140/90 millimetres of mercury (mmHg)\n             at the end of screening: If the single BP measurement is above 140 mmHg systolic or\n             90 mmHg diastolic, then the BP measurement can be repeated.  The subject must have 3\n             consecutive BP readings that are less than 140 mmHg systolic and 90 mmHg diastolic,\n             and each measurement must be separated by at least 15 minutes, to be eligible for\n             participation in this study.\n\n          -  A female subject is pregnant or nursing.\n\n          -  Positive serology for chronic infection: have a historically positive Human\n             Immunodeficiency Virus (HIV) test or test positive at screening for HIV, serologic\n             evidence of Hepatitis B (HB) infection based on the results of testing for hepatitis\n             B surface antigen (HBsAg), and anti- hepatitis B core antigen (HBc), positive test\n             for Hepatitis C antibody confirmed by HCV RNA.  If HCV RNA is not available, then the\n             positive test for Hepatitis C antibody alone would be exclusionary.\n\n          -  Subject having donated blood or blood products in excess of 500 mL within a 56 day\n             period prior to the first dose of the current study.\n\n          -  The subject has participated in a clinical trial where they previously received\n             losmapimod.\n\n          -  The subject has participated in a clinical trial and has received an investigational\n             product 30 days, 5 half-lives or twice the duration of the biological effect of the\n             investigational product (whichever is longer) prior to the first dose of the current\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000440", 
            "org_study_id": "117283"
        }, 
        "intervention": {
            "arm_group_label": "Losmapimod (GW856553X)", 
            "description": "Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)", 
            "intervention_name": "Losmapimod", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "GW856553", 
            "Focal segmental glomerulosclerosis (FSGS)", 
            "p38 mitogen-activated protein kinase (MAPK) inhibitor", 
            "losmapimod", 
            "nephrotic syndrome"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19140"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of Losmapimod to Reduce Proteinuria in Corticosteriod or Calcineurin Inhibitor Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The reduction in proteinurea will be assessed by responder analysis. A Responder is defined as >=50 percent reduction in proteinuria (Up/c ratio) from baseline with a maintenance of renal function (>=70 percent of baseline Estimated Glomerular Filtration Rate [eGFR])", 
            "measure": "Reduction in proteinuria at the end of treatment (>=16 weeks)", 
            "safety_issue": "No", 
            "time_frame": "From Baseline up to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000440"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The reduction in proteinurea will be assessed by responder analysis. A Responder is defined as >=50 percent reduction in proteinuria (Up/c ratio) from baseline with a maintenance of renal function (>=70 percent of baseline eGFR)", 
                "measure": "Reduction in proteinuria at any time during treatment", 
                "safety_issue": "No", 
                "time_frame": "From Baseline up to Week 24"
            }, 
            {
                "description": "Urine sample will be collected for evaluation of proteinuria responses including incidence of complete remissions which is defined as proteinuria Up/c <0.3 and maintenance of >=70 percent of baseline eGFR throughout treatment period", 
                "measure": "Proteinuria responses", 
                "safety_issue": "No", 
                "time_frame": "From Baseline up to Week 24"
            }, 
            {
                "description": "Safety and tolerability assessments including: adverse events (AEs), serious adverse events (SAEs), subject withdrawals due to toxicities, changes in clinical laboratory values (liver function tests [LFTs], serum creatinine, eGFR, cystatin C) and vital signs", 
                "measure": "Safety and tolerability of losmapimod", 
                "safety_issue": "No", 
                "time_frame": "From Baseline up to Week 36"
            }, 
            {
                "description": "Blood samples will be collected for the assessment of plasma exposure post first dose and area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC [0-t]) (7.5 mg), area under the plasma concentration-time curve during a dosage interval (AUC[0-tau]) (7.5 mg and 15 mg), and maximum observed concentration (Cmax) (7.5 mg)", 
                "measure": "Pharmacokinetics (PK) of losmapimod and metabolite (GSK198602)", 
                "safety_issue": "No", 
                "time_frame": "Baseline (pre-dose, 1, 2, 4, and 6 hours post-dose), Week 2 (pre-dose and 2 hours post-dose), Weeks 4, 8, 16 and 24 at one of the post-dose times (0 to 2 hours/2 to 4 hours/4 to 6 hours/6 to 8 hours post-dose)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}